Ventricular Tachycardia
Conditions
Brief summary
The purpose of this study is to determine the efficacy of VT ablation guided by functional evaluation of the substrate to specifically target the reentry-vulnerable zones in patients with infarct-related VT.
Detailed description
Activation mapping of VT is the gold-standard method for description of the reentrant circuit and identification of its isthmus, however this is uncommonly accomplished due to hemodynamic non-tolerance and limited temporal and spatial resolution. Substrate mapping has been developed as an alternative method to identify the isthmus of post-infarction VT during sinus rhythm (SR). However, it has limited specificity to critical VT sites. Fundamental work in animal models of healed infarction and humans has shown that the VT isthmus corresponds to locations characterized by marked activation slowing during SR. Furthermore, these locations serve as anchors for multiple VT morphologies and cycle lengths. The hypothesis of this study is that activation mapping during SR or pacing can improve the specifically for identifying the critical VT sites. The aim of this prospective, multi-center controlled study is to evaluate the utility and limitations of functional mapping for guiding ablation of reentry vulnerably zones for long-term control of VT
Interventions
DEVICEAblation
Cardiac Ablation
Sponsors
Boston Scientific Corporation
Center for Cardiovascular Reseach and Innovation
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
This prospective, multi-center controlled study enrolles patients with infarct-related VT refractory to anti-arrhythmic drugs. The outcome of the study group will be compared to historical control group of patients matched for age, LVEF and VT burden.
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years 2. History of myocardial infarction ≥1month before enrolment documented by ECG or cardiac imaging (TTE, SPECT, CMR). 3. Planned for first VT ablation procedure. 4. Patients must have an ICD or a plan for ICD implantation after the ablation. 5. Ability to understand the requirement of the study and to sign an informed consent.
Exclusion criteria
1. Patients requiring long-term treatment with class I or class III antiarrhythmic drugs after ablation (for AF). 2. The VT substrate is thought not to be related to coronary disease. 3. Presence of ongoing ischemia that is thought to be the cause of the VT. 4. Contraindication to anticoagulation therapy 5. Stroke within 30 days before enrollment. 6. Life expectancy \<1 year for any medical condition.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite of VT recurrence or death | 36 months follow-up |
Outcome results
None listed